No test can tell us with certainty which disease we will develop in the future. However, the risk of cardiovascular disease, type 2 diabetes, chronic kidney disease, bone and muscle loss, and some cancers can be meaningfully assessed years before symptoms appear.
The aim is not to try to predict the future, but to identify modifiable risks early, carry out appropriate screening at the right time and make decisions today that will extend healthy lifespan.
In my view, there is a very valuable test here: the biological age test. If your biological age is ahead of your chronological age, your risk of encountering age-related diseases is high. For this reason, the Biological Age Test deserves to be part of routine health screening.
In brief:
Can health risk be identified before disease begins?
For many chronic diseases, what can be calculated is not a definitive diagnosis, but the probability of developing disease in the future.
The strongest risk map considers family history, lifestyle habits, examination, blood pressure, selected laboratory tests and changes over time together.
Validated methods exist for cardiovascular, diabetes and kidney risk; genetic tests are more meaningful in specific family histories and when the result would change a medical decision.
Biological age tests, broad genetic panels, tumour markers and whole-body screening are not, on their own, reliable “tests of the future” in healthy people.
A good risk assessment should end with an actionable prevention and follow-up plan, not simply more data.
Can Future Health Risks Be Identified Before Disease Begins? A Personal Risk Map
Can a disease be recognised before it appears?
Some diseases leave biological traces before causing symptoms. Blood pressure may begin to rise, plaque may form in artery walls, glucose regulation may deteriorate, albumin may appear in urine or bone density may begin to decline. The person may still feel well in everyday life.
However, three different concepts need to be distinguished:
Risk assessment: Estimates the likelihood of developing disease in the future. For example, 10-year cardiovascular risk can be calculated using age, smoking, blood pressure and cholesterol.
Screening: Aims to detect disease or a precursor lesion early in a defined group without symptoms. Cervical, breast and colorectal cancer screening are examples.
Early diagnosis: Identifies an existing disease at an early stage following a symptom, examination finding or test result.
A high risk does not mean that the person has developed the disease. Low risk does not mean zero risk either. Risk estimates are like a compass: they do not reveal the future with certainty, but indicate which direction deserves closer attention.
How is a personal health risk analysis performed?
A good assessment does not consist of a single blood panel or device measurement. It is more appropriate to consider health risk in layers.
1. Predisposition: The underlying factors we cannot change
Chronological age, biological sex, family history and certain genetic characteristics affect baseline risk. In particular, heart attack, stroke, sudden death, type 2 diabetes, certain cancers, osteoporotic fracture or early-onset cognitive impairment in first-degree relatives at a young age may change the assessment.
For family history to be useful, simply saying “there is cancer in the family” is not enough. It is necessary to know who had the disease, which type it was and approximately how old they were when it appeared. This simple family health tree is often a better starting point than an indiscriminately ordered broad genetic panel.
2. Current risk burden: Factors measurable today
Indicators such as blood pressure, smoking, waist circumference, weight trend, physical activity, sleep, alcohol consumption, LDL cholesterol and glucose metabolism affect future risk. A substantial proportion of these can be changed.
The direction of change over time matters as well as a single “normal” value. Increasing waist circumference, blood pressure rising over the years or steadily worsening HbA1c even before it reaches a diagnostic threshold may be meaningful opportunities for early intervention.
3. Early organ involvement: Changes without symptoms
In selected individuals, investigations such as the urine albumin-to-creatinine ratio, fundus examination, bone density or coronary artery calcium score may provide information about organ involvement before clinical symptoms develop. However, these tests are not a standard package for everyone. If the result would not change a prevention or treatment decision, the value of the information remains limited.
4. Health capacity: Not just disease, but resilience
For a long and healthy life, we need to assess not only the likelihood of disease but also the person’s reserve. Muscle strength, balance, walking speed, cardiorespiratory capacity, sleep quality, cognitive function and psychological wellbeing do not appear in a standard laboratory panel.
A person may have no diagnosed disease, yet if their muscle strength and exercise capacity are low for their age, they may face an important risk to maintaining independence in later years. A personal risk map should therefore include not only “What condition do you have?” but also “What can you do, and how well can you do it?”
Can the risk of heart attack and stroke be identified in advance?
Cardiovascular disease is one of the fields in which risk prediction is most established. Validated models developed for Europe, such as SCORE2, combine information including age, smoking, systolic blood pressure, total cholesterol and HDL cholesterol to estimate the probability of fatal and non-fatal cardiovascular events over a specified period. [1]
This calculation is more meaningful than a cholesterol result alone. The same LDL value does not represent the same risk in a 35-year-old non-smoker with normal blood pressure and a 60-year-old with hypertension and a strong family history.
A basic assessment generally includes:
Home and clinic blood pressure measurements
Lipid profile and additional lipid markers when needed
Smoking and nicotine exposure
Diabetes or prediabetes status
Kidney function
Early cardiovascular disease in the family
Physical activity, waist circumference and body weight
In some people, lipoprotein(a), urinary albumin, chronic inflammatory diseases or a coronary artery calcium score may reclassify risk. The current European approach notes that risk modifiers and, where appropriate, imaging of subclinical atherosclerosis may contribute to assessment, particularly in people near a decision threshold. [2]
However, “more imaging” does not mean “better prevention”. Coronary CT angiography, carotid ultrasound or exercise stress testing should not be turned into a screening package without considering age, symptoms and baseline risk.
Can diabetes be recognised before it begins?
Type 2 diabetes usually does not begin in a single day. Insulin resistance, increasing weight and waist circumference, metabolic fatty liver disease, prediabetes and elevated blood pressure may develop years earlier. Fasting glucose, a 75-gram oral glucose tolerance test and HbA1c can be used for screening in appropriate individuals.
The American Diabetes Association’s 2026 standards recommend assessing risk factors or using a validated risk tool in asymptomatic adults, and considering testing regardless of age in those with overweight or obesity and an additional risk factor. In other adults, screening is recommended to begin no later than age 35. When to repeat a normal test depends on the initial result and changes in personal risk. [3]
The main factors that may increase risk include:
Type 2 diabetes in a first-degree relative
Increasing waist circumference or excess weight
Hypertension and elevated triglycerides
Physical inactivity
Polycystic ovary syndrome
A history of gestational diabetes
Metabolic fatty liver disease
Certain medicines and coexisting conditions such as sleep apnoea
A single fasting glucose result does not explain all metabolic risk. Results should be interpreted alongside waist circumference, blood pressure, lipids, liver health and changes over time.
Considering the possibility that the first abnormalities develop after meals, monitoring post-meal blood glucose and insulin levels, and using a continuous glucose sensor several times a year in at-risk individuals, can be helpful.
Can kidney disease be detected before symptoms appear?
Yes. Chronic kidney disease may remain asymptomatic for a long time. Particularly in people with diabetes, hypertension, cardiovascular disease or a familial risk of kidney disease, looking only at serum creatinine may not be sufficient.
The KDIGO 2024 guideline recommends assessing people at risk of kidney disease using both glomerular filtration rate and urine albumin. An abnormal eGFR or urine albumin-to-creatinine ratio should not be considered chronic disease on the basis of a single measurement; chronicity needs to be confirmed through repeated measurements and the clinical context. [4]
Increased urinary albumin may provide a warning of kidney and vascular risk before eGFR falls substantially. This early information may enable more careful planning of blood pressure, glucose, medicine and lifestyle management.
In addition to blood creatinine, checking cystatin C levels can also be useful during follow-up.
Can cancer risk be identified before disease begins?
Cancer is not a single disease, but many groups of diseases with different risk factors, biology and screening methods. The answer to “Is there one blood test that shows my cancer risk?” is therefore currently no.
The most strongly supported approach to cancer prevention has three components:
Reduce preventable factors: Avoid tobacco, maintain a healthy weight, stay active, limit alcohol, protect yourself from the sun and receive appropriate vaccinations.
Participate in screening appropriate to age and risk: Have cervical, breast and colorectal cancer screening on time according to national programmes.
Recognise family histories suggesting inherited predisposition: Cancer at a very young age, clusters of similar or related cancers in a family, more than one primary cancer in an individual or a known pathogenic variant may prompt genetic counselling.
The National Cancer Institute states that approximately 5–10% of cancers are thought to be associated with inherited harmful genetic changes, and that genetic testing should be planned after assessing personal and family history. A positive result does not mean “you will definitely develop cancer”, and a negative result does not mean “you have no cancer risk”. [5]
Tumour markers and multi-cancer early detection tests are not general tests that show future cancer risk in every healthy person. The performance of multi-cancer detection tests and the chain of follow-up procedures they generate are still being investigated; the NCI highlights the absence of randomised trials demonstrating that these tests reduce mortality. [6]
However, tests that detect circulating tumour DNA in the blood may enable early detection of more than 50 cancers while they are still undetectable by any imaging method.
Can dementia and Alzheimer’s risk be identified in advance?
A blood test or brain scan cannot tell a healthy person with certainty whether they will develop dementia years later. Nevertheless, many modifiable risks affecting lifelong brain health have been identified.
The 2024 Lancet Commission on Dementia addresses 14 modifiable risk areas: education, hearing loss, high LDL cholesterol, hypertension, smoking, obesity, depression, physical inactivity, diabetes, excessive alcohol consumption, traumatic brain injury, air pollution, social isolation and untreated vision loss. The Commission estimates that addressing these factors at population level could prevent or delay approximately 45% of dementia cases. Of course, this figure does not mean that one individual’s risk would fall by 45%. [7]
Brain health assessment is therefore not limited to a memory test. From midlife onwards, blood pressure, LDL cholesterol, diabetes, hearing and vision, movement, sleep, depression and social connections also matter. New or progressive forgetfulness requires a clinical assessment rather than risk calculation alone.
Today, brain age calculated using epigenetic clocks and artificial intelligence analysis of MRI images, together with blood p-tau 217, the AB42/40 ratio, NFL and GFAP levels, may make it possible to identify Alzheimer’s disease 10 years in advance.
Do genetic tests show future diseases?
The value of genetic testing depends on the question being asked.
High-impact variants associated with a single gene can be meaningful in certain hereditary syndromes. If there is a known pathogenic variant in the family, diseases occurring at a very young age or a clear cancer pattern, a test result may change the screening and prevention plan.
Polygenic risk scores combine the small effects of hundreds or thousands of common genetic variants. They are being studied for heart disease, diabetes and some cancers, but limitations include performance across populations of different ancestry, standardisation of clinical thresholds and whether the results genuinely translate into better health outcomes.
Genetic predisposition is not destiny. In most common chronic diseases, genes act together with the environment, behaviours, age and chance biological processes. A test should therefore be scrutinised carefully if it does not meet these three conditions:
Is the result reliable and can it be interpreted correctly?
Does the result add meaningful information to the existing risk estimate?
Will the result change monitoring, screening or treatment decisions?
Can a biological age test predict future diseases?
Epigenetic clocks and proteomic or metabolomic age scores are valuable tools for investigating the biological characteristics of ageing. They may show associations with disease and mortality risk at population level. However, telling someone “your biological age is 47” does not reveal which disease they will develop or when.
A review published in 2025 emphasised that epigenetic clocks are not yet sufficient for individual clinical decisions because of issues involving sample collection, laboratory processing, algorithms, tissue differences and individual reproducibility. [8]
These tests are useful as research and monitoring tools, but should be considered alongside actionable indicators and functional measurements such as blood pressure, LDL cholesterol, glucose, kidney function, smoking, muscle strength and cardiorespiratory capacity.
Can artificial intelligence and smartwatches predict diseases in advance?
Artificial intelligence can identify patterns in large volumes of data that the human eye may not readily detect. Smartwatches and wearable devices can also provide long-term trends in heart rate, activity, sleep duration and some rhythm irregularities.
However, for an algorithm to perform well, its data must be accurate, the device validated and the model tested in a similar population. False alarms may cause anxiety and unnecessary investigations, while false reassurance may lead to genuine symptoms being missed. A consumer device saying “normal” does not replace a medical assessment.
The best role for these tools is not as diagnostic authorities, but as aids that reveal changes over time alongside clinical history and validated measurements.
Why is screening for everything not safer?
“If finding disease before it begins is good, let us have every test” may initially sound logical. But screening can also cause harm:
False-positive result: A suspicious result when no disease is present
False-negative result: A reassuring test result despite disease or risk being present
Incidental finding: A change of uncertain health significance that triggers further procedures
Overdiagnosis: Identifying as a disease a condition that would never cause problems during the person’s lifetime
Unnecessary biopsy, radiation or intervention
Anxiety, cost and medical burden
The World Health Organization emphasises that a screening programme is more than a test: the target group, benefit–harm balance, confirmation process and care pathway following a positive result should be defined in advance. [9]
A good test is therefore not the one that produces the most data, but one whose result can be interpreted reliably and changes a decision that will improve health.
Before starting a programme, you can review the questions to ask when choosing a longevity programme about the purpose of tests and the follow-up process.
Where should you start to reduce future health risks?
1. Create your family health tree
Record important diseases in first- and second-degree relatives, the ages at diagnosis and, where possible, the types of disease. Heart attack, stroke, sudden death or cancer at an early age are particularly important.
2. Measure your basic health profile
Blood pressure, waist circumference, weight trend, smoking, movement, sleep, nutrition, mental health and age-appropriate basic laboratory tests should be assessed together. The test list should be selected individually.
3. Use validated risk calculations
Validated models appropriate to region and age can be used in areas such as cardiovascular risk. The result is not simply a “good” or “bad” label, but a tool for shared decision-making.
4. Personalise your screening schedule
National screening programmes appropriate to age and sex should form the basis; if family history or a particular risk is present, discuss with a physician whether an earlier or different programme is needed.
5. Add an advanced test only if it will change a decision
For a genetic panel, coronary calcium score, advanced imaging or a specialised biomarker, ask: “What will we do differently today if the result is high or low?” If there is no answer, the test’s clinical value may also be limited.
6. Turn risk into action and remeasure
Controlling blood pressure, stopping smoking, exercising regularly, increasing muscle strength, treating sleep apnoea and establishing a healthy weight and eating pattern may be more powerful than many expensive tests. The plan’s effects should be monitored at appropriate intervals using the same indicators.
Conclusion: The future cannot be read, but the direction of risk can be changed
Future health risks are often not completely invisible before disease begins. Family history, lifestyle, physical examination, validated risk models, selected laboratory tests and targeted imaging when necessary can create a meaningful risk map for the years ahead.
However, this map is not a prophecy. High risk does not mean certain disease, and low risk does not mean immunity. The most valuable assessment is not one that creates fear or offers everyone the same broad test package, but one that identifies modifiable risk, schedules appropriate screening and provides an achievable personal follow-up plan.
For me, the central question in preventive medicine is not “Can we say for certain what will happen in the future?” but “What right step can we take today to reduce an important future risk?”
This article provides general information. It does not replace a personal health assessment, diagnosis or treatment plan. New or worsening symptoms require a physician’s assessment rather than risk screening alone.
Frequently asked questions
Can blood tests reveal a disease before it begins?
Precursor changes in some diseases can appear in blood or urine tests, while others do not show up in standard testing. Which test is meaningful depends on age, symptoms, family history and personal risk. A normal result does not exclude all future risks.
Can a single test show every disease risk?
No. Cardiovascular, diabetes, cancer, kidney and brain health are assessed using different data and methods. Claims to “predict all diseases from a single drop of blood” go beyond current medical evidence.
How many years ahead can heart attack risk be calculated?
Models such as SCORE2 calculate 10-year cardiovascular event risk in certain age groups. Lifetime and 30-year models also exist, but the tool used should suit age, country and clinical circumstances. The calculated figure is a probability, not a certain outcome.
Will genetic testing tell me which diseases I will develop?
Usually not. In certain hereditary syndromes, genetic testing can provide powerful, actionable information. Most common chronic diseases, however, result from the combined effects of many genes, lifestyle and the environment. Genetic counselling before testing reduces misinterpretation.
Do tumour markers reveal cancer before disease begins?
Most tumour markers are not sufficiently accurate for general cancer screening in healthy people without symptoms. They may be elevated in benign conditions or remain normal when cancer is present. Cancer screening should follow age, sex, family history and evidence-based programmes.
Does a high biological age mean that I will become ill?
No. Biological age scores are useful for research and follow-up, but are not sufficiently standardised and validated to determine individual diagnoses or treatment decisions. Results can vary between tests and do not show when a particular disease will develop. They should be interpreted alongside multiple measurement systems.
How often should a health risk analysis be updated?
There is no universal interval. Age, existing diseases, medicines, family history, previous results and changes in living circumstances determine follow-up frequency. The plan may be updated sooner with new symptoms, a substantial weight change, pregnancy, menopause or a new diagnosis.
References
SCORE2 Working Group and ESC Cardiovascular Risk Collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. European Heart Journal. 2021;42(25):2439–2454. doi: 10.1093/eurheartj/ehab309
Mach F, Baigent C, Catapano AL, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal. 2025;46(42):4359–4378. doi: 10.1093/eurheartj/ehaf190
American Diabetes Association Professional Practice Committee. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1). doi: 10.2337/dc26-S002
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International. 2024;105(Suppl 4S)–S314. KDIGO 2024 CKD Guideline
National Cancer Institute. Genetic Testing for Inherited Cancer Risk. NCI Fact Sheet
National Cancer Institute. Cancer Screening Overview (PDQ®): Multi-Cancer Detection. NCI Cancer Screening Overview
Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. The Lancet. 2024;404(10452):572–628. doi: 10.1016/S0140-6736(24)01296-0
Apsley L, et al. From population science to the clinic? Limits of epigenetic clocks as personal biomarkers. Epigenomics. 2025;17(18). doi: 10.1080/17501911.2025.2603880
World Health Organization Regional Office for Europe. Screening programmes: a short guide. Increase effectiveness, maximize benefits and minimize harm. Copenhagen: WHO Regional Office for Europe; 2020. WHO publication
